<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MTB 报告 - None</title>
    <style>
        :root {
            --primary-blue: #1e40af;
            --light-blue: #3b82f6;
            --bg-blue: #eff6ff;
            --bg-white: #ffffff;
            --text-dark: #1f2937;
            --text-gray: #6b7280;
            --border-gray: #e5e7eb;
            --warning-red: #dc2626;
            --warning-bg: #fef2f2;
            --warning-yellow: #f59e0b;
            --success-green: #10b981;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Microsoft YaHei', sans-serif;
            background: linear-gradient(135deg, var(--bg-blue) 0%, var(--bg-white) 100%);
            color: var(--text-dark);
            line-height: 1.6;
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: var(--bg-white);
            border-radius: 16px;
            box-shadow: 0 4px 20px rgba(30, 64, 175, 0.1);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, var(--primary-blue) 0%, var(--light-blue) 100%);
            color: white;
            padding: 30px 40px;
        }

        .header h1 {
            font-size: 2em;
            margin-bottom: 10px;
        }

        .meta-info {
            display: flex;
            flex-wrap: wrap;
            gap: 20px;
            margin-top: 15px;
            font-size: 0.95em;
            opacity: 0.9;
        }

        .meta-info span {
            display: flex;
            align-items: center;
            gap: 5px;
        }

        .content {
            padding: 40px;
        }

        h2 {
            color: var(--primary-blue);
            font-size: 1.5em;
            margin-top: 30px;
            margin-bottom: 15px;
            padding-bottom: 10px;
            border-bottom: 2px solid var(--bg-blue);
        }

        h3 {
            color: var(--light-blue);
            font-size: 1.2em;
            margin-top: 20px;
            margin-bottom: 10px;
        }

        p {
            margin-bottom: 15px;
        }

        ul, ol {
            margin-left: 25px;
            margin-bottom: 15px;
        }

        li {
            margin-bottom: 8px;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 0.95em;
        }

        th {
            background: var(--primary-blue);
            color: white;
            padding: 12px 15px;
            text-align: left;
            font-weight: 500;
        }

        td {
            padding: 12px 15px;
            border-bottom: 1px solid var(--border-gray);
        }

        tr:hover td {
            background: var(--bg-blue);
        }

        .warning-box {
            background: var(--warning-bg);
            border-left: 4px solid var(--warning-red);
            padding: 15px 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }

        .warning-box strong {
            color: var(--warning-red);
        }

        .info-box {
            background: var(--bg-blue);
            border-left: 4px solid var(--light-blue);
            padding: 15px 20px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
        }

        .reference {
            color: var(--light-blue);
            text-decoration: none;
            position: relative;
            cursor: pointer;
            transition: color 0.2s;
        }

        .reference:hover {
            color: var(--primary-blue);
            text-decoration: underline;
        }

        .tooltip {
            position: absolute;
            background: var(--text-dark);
            color: white;
            padding: 8px 12px;
            border-radius: 6px;
            font-size: 0.85em;
            z-index: 100;
            max-width: 300px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
        }

        .evidence-tag {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 4px;
            font-size: 0.85em;
            font-weight: 500;
            margin-left: 5px;
        }

        .evidence-a { background: #dcfce7; color: #166534; }
        .evidence-b { background: #dbeafe; color: #1e40af; }
        .evidence-c { background: #fef3c7; color: #92400e; }
        .evidence-d { background: #fee2e2; color: #991b1b; }

        .footer {
            background: var(--bg-blue);
            padding: 20px 40px;
            text-align: center;
            color: var(--text-gray);
            font-size: 0.9em;
        }

        code {
            background: #f3f4f6;
            padding: 2px 6px;
            border-radius: 4px;
            font-family: 'Consolas', 'Monaco', monospace;
        }

        blockquote {
            border-left: 4px solid var(--light-blue);
            padding-left: 20px;
            margin: 15px 0;
            color: var(--text-gray);
            font-style: italic;
        }

        @media print {
            body { background: white; }
            .container { box-shadow: none; }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>分子肿瘤委员会（MTB）报告</h1>
            <div class="meta-info">
                <span><strong>患者编号:</strong> None</span>
                <span><strong>肿瘤类型:</strong> 乙状结肠癌</span>
                <span><strong>生成日期:</strong> 2026-01-17 12:37:00</span>
            </div>
        </div>

        <div class="content">
            <p>这里是基于多学科专家意见汇总生成的最终 MTB 报告。</p>
<hr />
<h1>分子肿瘤专家委员会 (MTB) 最终报告</h1>
<p><strong>报告日期</strong>: 2024年05月20日<br />
<strong>主审主席</strong>: MTB Chair<br />
<strong>患者 ID</strong>: [未提供]</p>
<hr />
<h2>1. 执行摘要 (Executive Summary)</h2>
<p><strong>Patient</strong>: 70岁男性，乙状结肠癌，IV期（既往接受10线治疗，难治性）。<br />
<strong>Key Molecular Findings</strong>: <strong>KRAS G12C</strong> (VAF 11.5%)，<strong>TMB-H (79 mut/Mb)</strong>，<strong>ATM 胚系突变</strong>。<br />
<strong>Current Status</strong>: 多线治疗后进展，肾功能受损 (Cr 146 μmol/L, eGFR ~40 mL/min)。<br />
<strong>Primary Recommendation</strong>: <strong>Sotorasib (索托拉西布) + Panitumumab (帕尼单抗)</strong>。<br />
<strong>Urgency</strong>: <strong>Urgent</strong> (患者处于难治性阶段，需尽快干预)。</p>
<p><strong>Summary</strong>:<br />
患者为极晚期乙状结肠癌，携带罕见的 KRAS G12C 突变及极高肿瘤突变负荷。尽管既往治疗已达10线，但分子特征提示存在高效的靶向及免疫治疗机会。首选推荐基于 CodeBreaK 300 研究的 <strong>KRAS G12C 抑制剂联合抗 EGFR 抗体</strong> 方案，该方案生存获益明确。考虑到患者肾功能不全，该方案安全性优于化疗。备选方案为 <strong>Pembrolizumab</strong> 免疫治疗。需特别注意 Sotorasib 与质子泵抑制剂 (PPI) 的严重相互作用。</p>
<hr />
<h2>2. 患者概况 (Patient Profile)</h2>
<h3>Demographics</h3>
<ul>
<li><strong>Age</strong>: 70 years</li>
<li><strong>Sex</strong>: Male</li>
<li><strong>ECOG PS</strong>: 1 (基于肿瘤学家报告推断)</li>
</ul>
<h3>Cancer Diagnosis</h3>
<ul>
<li><strong>Primary Cancer</strong>: 乙状结肠癌 (Sigmoid Colon Cancer)</li>
<li><strong>Histology</strong>: 腺癌 (Adenocarcinoma)</li>
<li><strong>Stage</strong>: IV期 (Metastatic)</li>
<li><strong>Treatment History</strong>: 既往接受 10 线系统治疗</li>
<li><strong>Current Status</strong>: 疾病进展 (PD)</li>
</ul>
<h3>Comorbidities &amp; Organ Function</h3>
<ul>
<li><strong>Renal</strong>: <strong>CKD 3期</strong> (Cr 146 μmol/L, eGFR ~35-45 mL/min) ⚠️</li>
<li><strong>Hepatic</strong>: 基线未知，需检测。</li>
</ul>
<hr />
<h2>3. 分子特征 (Molecular Profile)</h2>
<h3>Actionable Alterations</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Variant</th>
<th>Type</th>
<th>VAF</th>
<th>CIViC Level</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong></td>
<td><strong>G12C</strong> (c.34G&gt;T)</td>
<td>SNV</td>
<td>11.5%</td>
<td>Level B</td>
<td><strong>CodeBreaK 300 (Phase III)</strong></td>
</tr>
<tr>
<td><strong>TMB</strong></td>
<td><strong>79 mut/Mb</strong></td>
<td>Biomarker</td>
<td>N/A</td>
<td>Level B</td>
<td><strong>FDA Approved (Solid Tumors)</strong></td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td>Germline Pathogenic</td>
<td>Indel/SNV</td>
<td>~50%</td>
<td>Level C</td>
<td>Preclinical / Basket Trials</td>
</tr>
</tbody>
</table>
<h3>Immune Biomarkers</h3>
<ul>
<li><strong>MSI Status</strong>: MSS (微卫星稳定)</li>
<li><strong>TMB</strong>: <strong>High (79 mut/Mb)</strong> —— <em>提示潜在 POLE/POLD1 突变 ("Ultramutated" 表型)</em></li>
<li><strong>PD-L1</strong>: 未报告</li>
</ul>
<h3>Co-Alterations</h3>
<ul>
<li>无 NRAS/BRAF V600E 突变；无 HER2 扩增。</li>
</ul>
<hr />
<h2>4. 治疗史回顾 (Treatment History)</h2>
<table>
<thead>
<tr>
<th>Line</th>
<th>Regimen</th>
<th>Status</th>
<th>Key Observations</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-10</td>
<td>[Details unavailable]</td>
<td>Progressed</td>
<td>患者已对标准治疗（氟尿嘧啶、奥沙利铂、伊立替康、抗血管生成药、瑞戈非尼/TAS-102）耐药或不耐受。</td>
</tr>
</tbody>
</table>
<p><strong>Key Observations</strong>:<br />
- <strong>多重耐药</strong>: 经过10线治疗，肿瘤细胞可能已富集复杂的耐药克隆。<br />
- <strong>骨髓储备</strong>: 长期化疗可能导致骨髓抑制风险增加，需避免强效化疗。</p>
<hr />
<h2>5. 药物/方案对比 (Regimen Comparison)</h2>
<p>针对该患者的前 3 种选择对比：</p>
<table>
<thead>
<tr>
<th>Regimen</th>
<th>Evidence Level</th>
<th>ORR</th>
<th>mPFS</th>
<th>Key Toxicities</th>
<th>Cost/Access (China)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sotorasib + Panitumumab</strong></td>
<td><strong>A (NCCN Cat 1)</strong></td>
<td>~26%</td>
<td>5.6m</td>
<td>皮疹, 腹泻, 肝毒性</td>
<td>Sotorasib 需超适应症/自费; 帕尼单抗医保</td>
</tr>
<tr>
<td><strong>Pembrolizumab</strong></td>
<td><strong>B (FDA Approved)</strong></td>
<td>~30-40%*</td>
<td>Durable</td>
<td>免疫性炎症 (irAEs)</td>
<td>已上市 (自费/赠药)</td>
</tr>
<tr>
<td><strong>Regorafenib / TAS-102</strong></td>
<td>A (Standard)</td>
<td>&lt;5%</td>
<td>~2.0m</td>
<td>手足皮肤反应, 骨髓抑制</td>
<td>医保覆盖 (但患者可能已用过)</td>
</tr>
</tbody>
</table>
<p><em>*注：针对 TMB &gt; 50 mut/Mb 的超突变人群，ORR 可能显著高于普通人群。</em></p>
<p><strong>Comparison Summary</strong>:<br />
Sotorasib+Panitumumab 提供了目前最高级别的循证医学证据和生存获益。Pembrolizumab 虽为异病种批准，但鉴于 TMB 极高，可能带来“治愈性”的长拖尾效应。标准三线药物疗效微弱，不再推荐。</p>
<hr />
<h2>6. 器官功能与剂量 (Organ Function &amp; Dosing)</h2>
<h3>Current Organ Function &amp; Constraints</h3>
<table>
<thead>
<tr>
<th>System</th>
<th>Parameter</th>
<th>Value</th>
<th>Status</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Renal</strong></td>
<td><strong>Creatinine</strong></td>
<td><strong>146 μmol/L</strong></td>
<td>⚠️ <strong>Impaired</strong></td>
<td><strong>Monitor closely</strong></td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td><strong>eGFR</strong></td>
<td><strong>~41 mL/min</strong></td>
<td>⚠️ <strong>CKD 3b</strong></td>
<td><strong>Avoid Nephrotoxins</strong></td>
</tr>
<tr>
<td>Hepatic</td>
<td>ALT/AST</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Check Baseline</td>
</tr>
</tbody>
</table>
<h3>Dose Adjustments</h3>
<p><strong>For Recommended Regimen (Sotorasib + Panitumumab)</strong>:<br />
- <strong>Sotorasib</strong>:<br />
  - <strong>Renal</strong>: eGFR ≥ 30 mL/min <strong>无需调整剂量</strong>。<br />
  - <strong>Hepatic</strong>: 若治疗中 ALT/AST &gt;3x ULN，需暂停并减量。<br />
- <strong>Panitumumab</strong>:<br />
  - <strong>Renal</strong>: 单抗不经肾脏排泄，<strong>无需调整剂量</strong>。<br />
  - <strong>Skin</strong>: 需预防性使用多西环素（100mg BID）和保湿霜。</p>
<p><strong>Drug-Drug Interactions (Critical ⚠️)</strong>:<br />
- <strong>PPIs (质子泵抑制剂)</strong>: <strong>禁止联用</strong>（如奥美拉唑）。PPI 会显著降低 Sotorasib 吸收。<br />
- <strong>替代方案</strong>: 使用 H2 受体拮抗剂（如法莫替丁），需在 Sotorasib 服药前 4 小时或后 10 小时使用。</p>
<hr />
<h2>7. 治疗路线图 (Treatment Roadmap)</h2>
<h3>Immediate Next Step (Recommended)</h3>
<p><strong>Regimen</strong>: <strong>Sotorasib (960 mg PO QD) + Panitumumab (6 mg/kg IV Q2W)</strong><br />
<strong>Evidence Level</strong>: <strong>A</strong> (CodeBreaK 300 Phase III)<br />
<strong>Rationale</strong>: 针对 KRAS G12C 的特异性靶向，联合用药阻断 EGFR 反馈通路。对于 10 线治疗后的患者，这是唯一显示出显著 PFS 获益的方案。<br />
<strong>Expected Timeline</strong>: 每 6-8 周复查 CT。若耐受性好且 SD/PR，持续用药。</p>
<h3>Second-Line Options (If Progression)</h3>
<p><strong>Regimen</strong>: <strong>Pembrolizumab (200 mg IV Q3W)</strong><br />
<strong>Evidence Level</strong>: <strong>B</strong> (FDA TMB-H approval)<br />
<strong>Rationale</strong>: 利用极高 TMB (79 mut/Mb) 产生的肿瘤新抗原，激活免疫杀伤。若靶向治疗失败，此为最佳挽救手段。</p>
<h3>Third-Line Options</h3>
<p><strong>Clinical Trial</strong>: 针对 <strong>ATM 突变</strong> 的 PARP 抑制剂试验，或国产 KRAS G12C 抑制剂（如 Garsorasib, Fulzerasib）试验。</p>
<hr />
<h2>8. 分子复查建议 (Re-biopsy / Liquid Biopsy)</h2>
<p><strong>Timing</strong>: 疾病进展 (PD) 时。<br />
<strong>Method</strong>: <strong>液体活检 (ctDNA)</strong>。<br />
<strong>Purpose</strong>:<br />
1.  检测 <strong>KRAS G12C 耐药突变</strong> (如 Y96D)。<br />
2.  检测 <strong>MET 扩增</strong> (抗 EGFR 治疗的常见耐药机制)。<br />
3.  监测 TMB 动态变化。</p>
<hr />
<h2>9. 临床试验推荐 (Clinical Trials)</h2>
<p>鉴于 Sotorasib 在中国结直肠癌适应症尚未获批，参加国产同类药物临床试验是经济且可行的选择。</p>
<h3>Top Recommended Trials (China Sites)</h3>
<h4>Trial 1: Garsorasib (D-1553) for KRAS G12C CRC</h4>
<p><strong>Phase</strong>: II<br />
<strong>Drug</strong>: Garsorasib (D-1553) ± Cetuximab<br />
<strong>Target</strong>: KRAS G12C<br />
<strong>Status</strong>: Recruiting (China)<br />
<strong>Rationale</strong>: 国产强效 G12C 抑制剂，早期数据显示在 CRC 中具有良好疗效。<br />
<strong>Reference</strong>: <a href="https://clinicaltrials.gov/study/NCT05383898">NCT05383898</a></p>
<h4>Trial 2: Fulzerasib (IBI351)</h4>
<p><strong>Phase</strong>: Ib/II<br />
<strong>Drug</strong>: IBI351 + Cetuximab<br />
<strong>Target</strong>: KRAS G12C<br />
<strong>Status</strong>: Recruiting (China)<br />
<strong>Rationale</strong>: 信达生物研发，联合抗 EGFR 抗体治疗晚期结直肠癌。</p>
<hr />
<h2>10. 局部治疗建议 (Local Therapy)</h2>
<p><strong>Current Patient</strong>:<br />
目前为全身广泛转移（推测），且处于快速进展风险中，<strong>暂无局部治疗指征</strong>。<br />
若治疗后出现 <strong>寡进展 (Oligoprogression)</strong>（如仅肝脏单个病灶增大），可考虑 SBRT 或射频消融，以延长系统治疗的获益时间。</p>
<hr />
<h2>11. 核心建议汇总 (Core Recommendations)</h2>
<h3>Recommended Treatment Plan</h3>
<ol>
<li><strong>Immediate</strong>: <strong>Sotorasib (960mg QD) + Panitumumab (6mg/kg Q2W)</strong><ul>
<li><strong>Evidence</strong>: Level A (CodeBreaK 300)</li>
<li><strong>Safety</strong>: 肾功能安全，需监测肝酶。</li>
</ul>
</li>
<li><strong>Alternative (If Cost/Access is issue)</strong>: <strong>Pembrolizumab (200mg Q3W)</strong><ul>
<li><strong>Evidence</strong>: Level B (TMB-H &gt;10)</li>
<li><strong>Rationale</strong>: TMB 79 mut/Mb 提示极高获益可能。</li>
</ul>
</li>
<li><strong>Supportive</strong>:<ul>
<li><strong>皮肤管理</strong>: 强力保湿，预防性使用四环素类抗生素。</li>
<li><strong>遗传咨询</strong>: 针对 ATM 胚系突变进行家系验证。</li>
</ul>
</li>
</ol>
<h3>Not Recommended (Critical!)</h3>
<p><strong>DO NOT USE</strong>:<br />
1.  ❌ <strong>单药抗 EGFR 抗体 (西妥昔单抗/帕尼单抗)</strong>: KRAS G12C 突变导致原发耐药 <strong><span class="evidence-tag evidence-a">Evidence A</span></strong>。<br />
2.  ❌ <strong>质子泵抑制剂 (PPIs)</strong>: 与 Sotorasib 联用会导致药物失效 <strong>[FDA Warning]</strong>。<br />
3.  ❌ <strong>高剂量顺铂/大剂量 NSAIDs</strong>: 鉴于 eGFR ~40 mL/min，需保护残存肾功能。</p>
<hr />
<h2>12. 参考文献 (References)</h2>
<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/37870968/">PMID: 37870968 - Sotorasib plus Panitumumab in Refractory Colorectal Cancer (CodeBreaK 300)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/33020664/">PMID: 33020664 - Pembrolizumab in TMB-High Solid Tumors (KEYNOTE-158)</a></li>
<li><a href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1428">NCCN Guidelines for Colon Cancer v2.2024</a></li>
<li><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf">FDA Label - Sotorasib (Lumakras)</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/29337613/">PMID: 29337613 - KRAS G12C Inhibition in CRC (Preclinical Rationale)</a></li>
</ol>

            
            <div class="warning-box">
                <strong>⚠️ 安全警告</strong>
                <ul>
                
                    <li>- **Renal**: **CKD 3期** (Cr 146 μmol/L, eGFR ~35-45 mL/min) ⚠️</li>
                
                    <li>| **Renal** | **Creatinine** | **146 μmol/L** | ⚠️ **Impaired** | **Monitor closely** |</li>
                
                    <li>| **Renal** | **eGFR** | **~41 mL/min** | ⚠️ **CKD 3b** | **Avoid Nephrotoxins** |</li>
                
                    <li>**Drug-Drug Interactions (Critical ⚠️)**:</li>
                
                    <li>1.  ❌ **单药抗 EGFR 抗体 (西妥昔单抗/帕尼单抗)**: KRAS G12C 突变导致原发耐药 **[Evidence A]**。</li>
                
                </ul>
            </div>
            

            
            <h2>参考文献</h2>
            <ol>
            
                <li>
                    <a href="https://clinicaltrials.gov/study/NCT05383898" class="reference" target="_blank">
                        [NCT: NCT05383898]
                    </a>
                </li>
            
            </ol>
            
        </div>

        <div class="footer">
            <p>本报告由 MTB 多智能体系统自动生成 | 2026-01-17 12:37:00</p>
            <p>⚠️ 本报告仅供参考，所有临床决策应由具有资质的医疗专业人员做出</p>
        </div>
    </div>
</body>
</html>